Over the last several years, light-emitting therapy masks intended to treat acne have streamed into the marketplace and onto Instagram, filling feeds with pictures of people that resemble space-age hockey goalies. Neutrogena’s version of the product, which the company said would kill acne bacteria and fight “inflammation,” cost between $30 and $40, making it one of the more affordable masks on the market.

But earlier this month Neutrogena issued a recall of its masks, citing a “theoretical risk of eye injury” to a subset of people who had underlying eye conditions or were taking medicine that made them sensitive to light.

Neutrogena said in a statement that its July 5 recall followed “reports of mild, transient visual adverse events, combined with a growing scientific discussion around the safety of blue light.”

A spokeswoman said that the “adverse events” had been caused by the Neutrogena masks, though did not specify how many such events had taken place. She also said that no particular study or expert had informed the company’s decision to recall the masks.